ClinicalTrials.gg
RecruitingNCT06537453UPTAKE-VCUpdated Nov 10, 2026

UPTAKE - Virtual Care: Virtual Home Hospital With Remote Monitoring to Reduce Acute Care Hospitalization

An interventional study of Virtual Care in Acute Kidney Injury, sponsored by University of Calgary. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Calgary · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Acute Kidney Injury with a site in Canada — 19 open to participants now, 22 under way, 1 of them phase 3. Acute Kidney Injury · Canada.

Planned enrollment
14th of 54
354 · median 137
Started
2024
with 6 others
No phase
21 of 83
7 open now
Primary completion
2027-06
later than 12 of 21 live
Registered
73rd of 83
by date
Lead sponsor
4 of 83
University of Calgary

Among the 83 studies in Acute Kidney Injury with a site in Canada, this one is the 14th largest by planned enrollment of the 54 interventional ones that give a count, is one of 7 that started in 2024, is one of 21 with no phase, reaches primary completion later than 12 of the 21 other live ones, and was the 73rd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

19 of the 83 studies in Acute Kidney Injury with a site in Canada are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Acute Kidney Injury with a site in Canada, or all of them as a file.
02

Study summary

Method: Randomized Controlled Trial Study Duration: 3 Years Study Centre(s) University of Calgary and University of Alberta Objectives: To fill care gaps by implementing strategies to reduce length of hospital stay, readmission rates, and improve long-term outcomes after Acute Kidney Injury (AKI). Number of Participants: Three Hundred and fifty four (n=354) Diagnosis and Main Inclusion Criteria: Hospitalized adults with AKI at high risk of hospital readmission or death

Study Intervention: Multi-component Digital Health Solutions, including:

  1. Computerized Clinical Decision Support (CDS) and
  2. Virtual Care Delivered through Hospital at Home (VC) Duration of administration: Determined by the Patient's clinical team Reference therapy: Usual Care Statistical Analyses: Descriptive Analysis, Regression
Read the detailed description
  1. Background and Rationale

    Acute kidney injury (AKI) is a common and serious complication in hospitals. A major care gap for survivors of AKI is the fragmentation of care that exists as they transition from the hospital to their home. This contributes to a high risk of adverse long-term outcomes, including prolonged hospitalization, high rates of readmission, cardiovascular events, infections, progression to chronic kidney disease (CKD), kidney failure requiring dialysis, and death.

    To address this challenge, the investigators are implementing multi-component digital health solutions including Computerized Clinical Decision Support (CDS) and Digital Remote Patient Monitoring (dRPM) through Virtual Care (VC) programs in Alberta to reduce length of hospital stay and readmission rates and improve long-term outcomes after AKI.

    Evidence of the effectiveness of the two digital health solutions is available from Alberta and international clinical trials. Our team previously implemented a computerized CDS intervention for AKI risk assessment and prevention and achieved improved AKI prevention and reduced AKI incidence after cardiac procedures across the province. The investigators will use a similar approach to identify high risk patients with AKI and provide recommendations to improve the quality of their care, which is well suited to the evolving digital health infrastructure in Alberta.

    Providing hospital-level care at home through Virtual Care (VC) teams has been shown to reduce mortality and readmission rates. Alberta's VC program have existed in both Edmonton and Calgary since 2018 and have reported lower readmission rates, Emergency Department (ED) visits and use of Emergency Medical Services than observed with usual care. Patients reported that the program helped them regain their independence and function. Alberta's VC programs have implemented dRPM technology, which has been further associated with fewer days in hospital and emergency department visits. Patients reported better quality of care using this technology. The framework for dRPM and complex care planning is already in place in Alberta's Virtual Care programs. The investigators intend to utilize these programs to improve transitions of care through early facilitated discharge and enhanced follow-up of patients with AKI at high risk of hospital readmission, who require frequent monitoring and more intensive care strategies during this vulnerable period of transition in care.

  2. Research Question and Objectives

    • Implement and evaluate a transition of care intervention for patients with AKI.
    • Integrate digital health solutions that can achieve levels of monitoring and care in a patient's own home that are comparable to acute care, while transitioning care to the community setting.
    • Reduce the length of hospital stay and risk of hospital readmission for people with AKI.
    • Improve the long-term outcomes after hospitalization with AKI.
  3. Methods

The investigators will evaluate implementation initially in a Vanguard phase to establish feasibility and acceptability of the intervention, followed by an evaluation of implementation and effectiveness of the intervention in a larger Multicenter Randomized Controlled Trial (RCT). High risk patients with AKI and a predicted risk of readmission or death ≥20% will be identified using a Best Practice Alert (BPA) in Connect Care and participants will be randomized to care with or without virtual monitoring through the VC programs. All patients will receive the same baseline interventions refined in the Vanguard phase, while the intervention arm will additionally receive VC with dRPM following discharge.

High risk patients in the intervention arm will be navigated through the transition of care pathway by a trained nurse navigator. Patients will receive dRPM kits, and biometric data will be automatically uploaded to the web-based monitoring platform and reviewed by the nurse navigator. Patients will receive regular virtual assessments via telephone or videoconferencing (via the tablet) after in-patient discharge. Blood tests will be drawn at home by community paramedics as deemed necessary by the clinical team to assess kidney function and monitor for complications of AKI. Should concerns be identified that warrant in-person assessment, paramedic care teams will be sent for assessment and/or intervention. Upon completion of the intervention patients will be assessed for readiness to move to the subacute arms of the program and return to their primary care provider. If ongoing nephrologist or other specialist care is required, the nurse navigator will ensure appropriate follow up is arranged.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old.
  • AKI identified in hospital using Kidney Disease Improving Global Outcomes (KDIGO) criteria17.
  • Hospitalization > 48 hours.
  • LACE (L= Length patient Stay in the hospital, A= Acuity of Admission of patient in the hospital, C= Comorbidity and E= Emergency Visit.) Score 12 or higher.
  • Meets all inclusion criteria of Virtual Home Hospital programs of Calgary and Edmonton zones.

Exclusion criteria

Exclusion Criteria:

  • Non-Alberta residents.
  • Resides outside the catchment areas for the Calgary and Edmonton Virtual Home Hospital programs.
  • C1 or C2 goals of care.
  • Hospitalization > 30 days.
  • Will be discharged to long-term care.
  • Kidney failure receiving dialysis.
  • Already admitted in Virtual Home Hospital Program
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
354 participants (estimated)

Study arms

  • Experimental
    Virtual Care

    Participants will receive virtual care through Virtual Home Hospital programs in Alberta for their hospital to home transition of care.

    Other: Virtual Care

  • No intervention
    Usual Care

    Participants will be discharged as per usual care practices from hospital to their home.

Interventions

  • OtherVirtual Care

    Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.

06

What researchers measure

Primary outcomes

  1. the number of days alive out of hospital

    the number of days alive out of hospital

    Time frame: Up to 45 days from the date of randomization

Secondary outcomes

  1. the time as inpatient in hospital

    the time as inpatient in hospital

    Time frame: Up to 45 days from the date of randomization

  2. death

    death records from health administrative data.

    Time frame: from the date of randomization up to 45 days, or date of death from any cause, whichever came first,

  3. hospital readmission

    hospital readmission records from health administrative data.

    Time frame: Up to 45 days from the date of randomization

  4. Emergency Department visits

    Emergency Department visit records from health administrative data.

    Time frame: Up to 45 days from the date of randomization

  5. Estimated Glomerular Filtration (eGFR)

    eGFR

    Time frame: At 90 days after the date of randomization

  6. Urine Albumin Creatinine Ration (ACR)

    ACR laboratory test

    Time frame: At 90 days after the date of randomization

  7. total number of physician visits

    total number of physician visits

    Time frame: Up to 45 days from the date of randomization

  8. number of physician visits by specialty

    primary care vs. non-primary care

    Time frame: Up to 45 days from the date of randomization

  9. Changes to medication prescription

    Changes to medication prescription (including starting, stopping, or dose adjustment) of an Angiotensin-Converting Enzyme Inhibitors (ACEI)/Angiotensin receptor blockers (ARB), diuretic, SGLT2 inhibitor, or NSAID or administration of IV fluid

    Time frame: Up to 45 days from the date of randomization

  10. laboratory testing

    Number of creatinine/eGFR, electrolytes, and urine protein quantification

    Time frame: Up to 45 days from the date of randomization

  11. patient experience care transition measure

    Online Survey

    Time frame: At 45 days after the date of randomization

  12. Euro Qol- 5 Dimension (EQ5D)

    Online Survey to assess quality of life mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" to "extreme problems

    Time frame: At 45 days after the date of randomization

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ. 2005 Apr 2;330(7494):765. doi: 10.1136/bmj.38398.500764.8F. Epub 2005 Mar 14. PubMed 15767266 ↗
  • Roshanov PS, Fernandes N, Wilczynski JM, Hemens BJ, You JJ, Handler SM, Nieuwlaat R, Souza NM, Beyene J, Van Spall HG, Garg AX, Haynes RB. Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. BMJ. 2013 Feb 14;346:f657. doi: 10.1136/bmj.f657. PubMed 23412440 ↗
  • James MT, Har BJ, Tyrrell BD, Faris PD, Tan Z, Spertus JA, Wilton SB, Ghali WA, Knudtson ML, Sajobi TT, Pannu NI, Klarenbach SW, Graham MM. Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial. JAMA. 2022 Sep 6;328(9):839-849. doi: 10.1001/jama.2022.13382. PubMed 36066520 ↗
  • James MT, Har BJ, Tyrrell BD, Ma B, Faris P, Sajobi TT, Allen DW, Spertus JA, Wilton SB, Pannu N, Klarenbach SW, Graham MM. Clinical Decision Support to Reduce Contrast-Induced Kidney Injury During Cardiac Catheterization: Design of a Randomized Stepped-Wedge Trial. Can J Cardiol. 2019 Sep;35(9):1124-1133. doi: 10.1016/j.cjca.2019.06.002. Epub 2019 Jun 7. PubMed 31472811 ↗
  • Caplan GA, Sulaiman NS, Mangin DA, Aimonino Ricauda N, Wilson AD, Barclay L. A meta-analysis of "hospital in the home". Med J Aust. 2012 Nov 5;197(9):512-9. doi: 10.5694/mja12.10480. PubMed 23121588 ↗
  • Goncalves-Bradley DC, Iliffe S, Doll HA, Broad J, Gladman J, Langhorne P, Richards SH, Shepperd S. Early discharge hospital at home. Cochrane Database Syst Rev. 2017 Jun 26;6(6):CD000356. doi: 10.1002/14651858.CD000356.pub4. PubMed 28651296 ↗
  • Grinman, M., Kozicky, R. & Smith, M. Bringing Acute General Internal Medicine Outside of Hospital Walls. Canadian Journal of General Internal Medicine 17, 548 (2022
  • Gibbons-Reid, V., Wodinski, L. & Reynolds, C. Early Adoption & Implementation of Digital Remote Patient Monitoring in Virtual Hospital Care: Evaluation Report. Health Systems Evaluation and Evidence. (2021).
  • McGillion MH, Parlow J, Borges FK, Marcucci M, Jacka M, Adili A, Lalu MM, Ouellette C, Bird M, Ofori S, Roshanov PS, Patel A, Yang H, O'Leary S, Tandon V, Hamilton GM, Mrkobrada M, Conen D, Harvey V, Lounsbury J, Mian R, Bangdiwala SI, Arellano R, Scott T, Guyatt GH, Gao P, Graham M, Nenshi R, Forster AJ, Nagappa M, Levesque K, Marosi K, Chaudhry S, Haider S, Deuchar L, LeBlanc B, McCartney CJL, Schemitsch EH, Vincent J, Pettit SM, DuMerton D, Paulin AD, Simunovic M, Williams DC, Halman S, Harlock J, Meyer RM, Taylor DA, Shanthanna H, Schlachta CM, Parry N, Pichora DR, Yousuf H, Peter E, Lamy A, Petch J, Moloo H, Sehmbi H, Waggott M, Shelley J, Belley-Cote EP, Devereaux PJ; PVC-RAM-1 Investigators. Post-discharge after surgery Virtual Care with Remote Automated Monitoring-1 (PVC-RAM-1) technology versus standard care: randomised controlled trial. BMJ. 2021 Sep 30;374:n2209. doi: 10.1136/bmj.n2209. PubMed 34593374 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2027, 34 months after the start.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 34 months is above that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Aug 2026 → Jun 2027 and completion Oct 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 5, 2024
StartActual
Aug 10, 2024
Primary completionEst.
Jun 30, 2027was Aug 2026
CompletionEst.
Dec 31, 2027was Oct 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 10, 2026→Jun 30, 2027
Nov 10, 2026
Study completion
Oct 31, 2026→Dec 31, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Aug 10, 2026→Jun 30, 2027
    Study completion Oct 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06537453
Collaborators
Alberta Health services
Responsible party
Sponsor
First posted
Aug 5, 2024
Start date
Aug 10, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Director
Contact
cccr@ucalgary.ca
+1 (403) 210. 6730
Matthew James, MD
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion